NIH Launches Clinical Trial of Epstein-Barr Virus Vaccine

National Institute of Allergy and Infectious Diseases sent this bulletin at 05/06/2022 03:20 PM EDT

Friday, May 6, 2022

NIH Launches Clinical Trial of Epstein-Barr Virus Vaccine

NIAID scientists are working to develop the first vaccine for the Epstein-Barr virus, a type of herpes virus linked to some cancers and autoimmune diseases.
EBV, one of the most common types of viruses, is transmissible through saliva and the primary cause of infectious mononucleosis, sometimes called the “kissing disease.” Mononucleosis can cause long bouts of fatigue in some people. The phase 1 trial, conducted by NIAID’s Laboratory of Infectious Diseases, will enroll 40 volunteers ages 18 to 29. It is expected to last four years.

National Institute of Allergy and Infectious Diseases | National Institutes of Health

Update your subscriptions, modify your password or e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact Subscriber Help.

This service is provided to you at no charge by National Institute of Allergy and Infectious Diseases (NIAID).